我国将力争在年底前完成3至11岁人群新冠疫苗接种

10月30日举行的国务院联防联控机制新闻发布会上，国家卫健委疾控局副局长吴良有表示，我国将力争在年底前完成3至11岁人群新冠疫苗接种。

 

吴良有介绍：

 

China has approved three domestic COVID-19 vaccines² for emergency use in children aged³ 3 to 11. Two inactivated⁴ vaccines developed by Sinopharm and one inactivated vaccine¹ created by Sinovac Biotech have been cleared for emergency use in people aged 3 to 11.

 

目前国药中生北京所、武汉所，科兴中维的新冠灭活疫苗已经获准在3至11岁人群中开展紧急使用。

 

吴良有表示，根据科研攻关组疫苗研发专班专家论证意见，新冠病毒灭活疫苗在3—11岁人群中的安全性和免疫原性，与18岁以上人群没有显著性差异(inactivated COVID-19 vaccines are as safe and effective among people aged 3 to 11 as they are in people aged over 18)。国务院联防联控机制根据相关工作进展，综合考虑我国疫苗生产能力、接种能力、临床试验情况和防控工作实际，进一步扩大了接种范围（authorities have taken manufacturing and inoculation⁵ capacity, clinical trial results and epidemic⁶ situation into consideration, and decided⁷ to further expand its immunization campaign），将疫苗接种目标人群由12岁以上调整至3岁以上。

 

吴良有说，我们将继续按照知情、同意、自愿的原则（abide⁸ by the principles of voluntary participation⁹ and informed consent），积极引导3至11岁无禁忌人群应接尽接，力争12月底前完成全程接种(aim to vaccinate¹⁰ all eligible¹¹ children by this year's end)。同时，要求接种点有儿科急诊急救人员，还有儿童急救药品保障。截至10月29日，已经接种353万剂次( 3.53 million doses had been delivered to the age group)。

 

谈及儿童接种新冠病毒疫苗的必要性，中国疾控中心免疫规划首席专家王华庆在会上指出，过去认为，儿童新冠肺炎发病率较低，但随着疫情的传播和流行，现在儿童的发病水平和去年年底成人发病水平已经接近或增加(incidence rates of COVID-19 in young people in some countries are rising and even nearing the rates among adults, challenging the previous perception that children are at lower risk of contracting the virus)，因此给儿童接种疫苗有其必要性。

 

王华庆提醒，3岁-11岁儿童可能还要接种其他疫苗，务必让新冠病毒疫苗与其他疫苗接种间隔14天以上(since many minors¹² also need to receive other vaccines in the national vaccination¹³ program,  different vaccines should be given at least 14 days apart)。如果必须接种狂犬病疫苗、破伤风疫苗等，可以不考虑时间间隔的要求。

分享到：